Schizophrenia associated gene, proteins and biallelic markers
CA 2388205 A1 · Owner: Essioux, Laurent · Inventors: Blumenfeld, Marta; Cohen, Daniel; Chumakov, Ilya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns the human g35030 gene polynucleotides, polypeptides , biallelic markers and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the g35030 gene and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases means to , determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 4, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 4, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 4, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.